Enhancing the Development of AAV-Based Therapeutics With Mass Photometry
Adeno-associated vectors (AAVs) are transforming therapeutics – from gene therapy to vaccines.
A major challenge when developing AAV-based therapeutics is ensuring that empty AAVs that lack therapeutic DNA are removed, increasing the efficacy of the product.
But the empty AAVs are chemically identical to their full counterparts, making this process complicated. Enter mass photometry, a new bioanalytical technique that can efficiently characterize AAVs and distinguish between full and empty AAVs.
This webinar explores how mass photometry can circumvent challenges associated with AAVs, helping to accelerate therapeutic development and manufacturing.
Attend this webinar to:
- Discover how mass photometry is currently being used in industry
- Learn how mass photometry can accurately measure empty/full AAV capsid ratios
- Explore how to integrate mass photometry in a GMP-regulated environment
Will I receive a certificate of attendance?
Yes, when attending the webinar, you will be able to download a certificate of attendance from the literature section.
Will the webinar be available to watch On-Demand?
Yes, after the live date the recording will be available to watch. Once registered, you will receive an email notifying you when the recording is available along with your on-demand link.
- Presenter: Dr. Matt Ranaghan (Senior Applications Scientist, Refeyn)
